Torrent Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 27.4%)
- Efficient capital deployment (ROCE 15.2%)
Concerns
- Premium to sector peers (P/E 79.3x vs industry 50.2x)
- High premium to book value (P/B 9.4x)
Today's Price Action
The stock closed at ₹4,557, identical to the previous close, registering zero percent change. Trading volume matched the 20‑day average at 2,26,143 shares, indicating a routine level of market participation without any immediate imbalance between supply and demand.
Valuation Snapshot
The current price‑to‑earnings multiple stands at 79.3, markedly higher than the sector average, which is effectively zero due to a mix of loss‑making peers. A price‑to‑book ratio of 0.9 sits below the nominal 1.0 threshold, while the return on equity of 27.4 % underscores strong profitability relative to the capital base.
Key Levels to Watch
The price sits roughly 20 % above the 52‑week low of ₹3,533 and about 13 % below the 52‑week high of ₹5,250, placing it in the upper‑mid range of its yearly trading corridor. Open‑interest data from the nearest futures expiry shows a modest cluster of contracts around the ₹4,600–₹4,650 band, suggesting a potential short‑term liquidity zone.
Chart Pattern
On the daily chart, two bullish engulfing candles were recorded—one seven trading days ago and another two days ago—accompanied by a morning‑star formation also two days back. These candlesticks typically signal a transition from a down‑trend to a consolidation or nascent up‑trend, reflecting a shift in short‑term price dynamics.
Data Summary
Key metrics include a P/E of 79.3, a P/B of 0.9, and an ROE of 27.4 %, all recorded against a market‑cap that currently registers as nil in the data feed. The 52‑week range spans ₹3,533 to ₹5,250, with recent volume aligning precisely with the 20‑day average of 2,26,143 shares.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,335 | ₹1.0L Cr | 36.6 | 2.87 | 11.2 | 13 | 0.19 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
TORNTPHARM · as of Dec 2025
| Category | Jul 2026 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Promoters | 68.31% | 71.25% | 71.25% | 71.25% | 71.25% | 68.31% |
| FII | 15.92% | 14.08% | 14.14% | 14.22% | 14.46% | 16.17% |
| DII | 9.17% | 7.11% | 7.15% | 7.17% | 6.98% | 8.25% |
| Public | 6.47% | 7.46% | 7.34% | 7.25% | 7.21% | 7.17% |
| Govt | 0.10% | 0.10% | 0.10% | 0.10% | 0.10% | 0.10% |
Corporate Events
To consider other business matters
the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-26.
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 9 Per Share
To consider and approve the financial results for the period ended March 31, 2026, dividend, Fund Raising and other business matters
Interim Dividend - Rs 29 Per Share
Record: 18 Feb 2026
Dividend - Rs 6 Per Share
Interim Dividend - Rs 26 Per Sh
Record: 31 Jan 2025
Dividend - Rs 6 Per Share
Interim Dividend - Rs 22 Per Share
Latest News
All newsTorrent Pharma acquires US-based drug firm for $120M
*Torrent Pharma acquires US-based drug firm for $120M*. The company has acquired a US-based pharmaceutical business for **$120 million**, expanding its footprint in the highly regulated US generics market. This strategic move is expected to enhance its product portfolio and revenue stream. The acquisition is funded through internal accruals and debt. 📊 *STOCKS:* $TORNTPHARM | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
Infosys, Tata Motors, Torrent Pharma among firms reporting Q2 earnings
*Infosys, Tata Motors, Torrent Pharma among firms reporting Q2 earnings* — Key NSE-listed companies including INFY, TATAMOTORS, and TORNTPHARM announce Q2 financial results today. Investors will watch for **revenue growth**, **margin performance**, and **guidance updates** amid macro uncertainties. Earnings could trigger sharp F&O movements in tech, auto, and pharma sectors. 📊 *STOCKS:* INFY, TATAMOTORS, TORNTPHARM | 🏢 *SECTOR:* Earnings | #HIGHIMPACT #Earnings
Torrent Pharma, JB Chemicals merger nears completion
*Torrent Pharma, JB Chemicals merger nears completion.* Talks are advancing despite **valuation disagreements** between the two pharma firms. The deal could reshape market positioning in India’s domestic pharmaceutical space. A final decision is expected within weeks. 📊 *STOCKS:* TORNTPHARM, JBMA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Merger
Torrent Pharma to host investor meet for updates
*Torrent Pharma to host investor meet for updates.* The company will conduct an analyst and institutional investor meet to discuss business performance and strategy. No major announcements expected, but guidance clarity may influence sentiment. The event is part of routine investor engagement. 📊 *STOCKS:* $TORNTPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Torrent Pharma announces general corporate updates
*Torrent Pharma announces general corporate updates.* The company filed routine corporate updates with the NSE, disclosing no major financial or operational changes. Details remain unspecified in the brief filing. **No significant impact** expected on near-term trading. 📊 *STOCKS:* $TORNTPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Torrent Pharma announces postal ballot via newspaper notice
*Torrent Pharma announces postal ballot via newspaper notice.* The company has published a notice in newspapers regarding the postal ballot process. This is part of routine corporate governance to seek shareholder approvals on specific matters. Details of the resolution are available in the official filing. 📊 *STOCKS:* $TORNTPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateAction
Torrent Pharma updates analysts on investor meet
*Torrent Pharma updates analysts on investor meet.* Company representatives discussed recent performance and future outlook during the analyst and institutional investor meet. No major financial announcements or guidance changes were disclosed. The session focused on strategic initiatives and business updates. 📊 *STOCKS:* $TORNTPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Torrent Pharma announces general corporate updates
*Torrent Pharma announces general corporate updates.* The company filed routine corporate updates with the NSE. No specific financial or operational details were disclosed. Such filings typically include administrative or procedural information. 📊 *STOCKS:* TORNTPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
Torrent Pharma gets FDA approval for new drug
*Torrent Pharma gets FDA approval for new drug* — The company received FDA nod for its **Valsartan** tablets, boosting its U.S. generics portfolio. This approval enhances export potential and may contribute to revenue growth. Market reaction expected positive on volume support. 📊 *STOCKS:* TORNTPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.3K Cr 0.0% | ₹3.3K Cr 3.9% | ₹3.2K Cr 7.4% | ₹3.0K Cr 5.3% | ₹2.8K Cr 2.8% | ₹2.9K Cr 1.0% | ₹2.9K Cr 4.2% | ₹2.7K Cr |
| Op. Profit | ₹1.1K Cr 0.5% | ₹1.1K Cr 4.9% | ₹1.0K Cr 7.1% | ₹964 Cr 5.5% | ₹914 Cr 2.7% | ₹939 Cr 3.9% | ₹904 Cr 2.4% | ₹883 Cr |
| OPM | 33.0% 0.0% | 33.0% 3.1% | 32.0% 3.0% | 33.0% 0.0% | 33.0% 3.1% | 32.0% 0.0% | 32.0% 0.0% | 32.0% |
| Net Profit | ₹635 Cr 7.4% | ₹591 Cr 7.8% | ₹548 Cr 10.0% | ₹498 Cr 1.0% | ₹503 Cr 11.0% | ₹453 Cr 0.9% | ₹457 Cr 1.8% | ₹449 Cr |
| EPS (₹) | 18.76 7.4% | 17.46 7.8% | 16.19 10.1% | 14.71 1.0% | 14.86 11.1% | 13.38 0.9% | 13.5 1.7% | 13.27 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14.0K Cr 21.4% | ₹11.5K Cr 7.3% | ₹10.7K Cr 11.5% | ₹9.6K Cr 13.1% | ₹8.5K Cr 6.3% | ₹8.0K Cr 0.8% | ₹7.9K Cr 3.5% | ₹7.7K Cr 29.0% | ₹6.0K Cr 2.3% | ₹5.8K Cr |
| Expenses | ₹9.4K Cr 20.9% | ₹7.8K Cr 5.9% | ₹7.4K Cr 8.6% | ₹6.8K Cr 11.5% | ₹6.1K Cr 10.0% | ₹5.5K Cr 4.2% | ₹5.8K Cr 1.4% | ₹5.7K Cr 23.7% | ₹4.6K Cr 3.7% | ₹4.4K Cr |
| Op. Profit | ₹4.6K Cr 22.5% | ₹3.7K Cr 10.5% | ₹3.4K Cr 18.5% | ₹2.8K Cr 16.9% | ₹2.4K Cr 2.0% | ₹2.5K Cr 14.3% | ₹2.2K Cr 9.4% | ₹2.0K Cr 47.0% | ₹1.3K Cr 2.0% | ₹1.4K Cr |
| OPM | 33.0% 3.1% | 32.0% 3.2% | 31.0% 3.3% | 30.0% 3.4% | 29.0% 6.5% | 31.0% 14.8% | 27.0% 3.8% | 26.0% 13.0% | 23.0% 4.2% | 24.0% |
| Other Income | ₹-182 Cr 18100.0% | ₹-1 Cr 100.7% | ₹146 Cr 224.4% | ₹45 Cr 115.6% | ₹-288 Cr 605.3% | ₹57 Cr 52.9% | ₹121 Cr 140.3% | ₹-300 Cr 200.3% | ₹299 Cr 34.1% | ₹223 Cr |
| Interest | ₹385 Cr 52.8% | ₹252 Cr 28.8% | ₹354 Cr 6.3% | ₹333 Cr 30.6% | ₹255 Cr 27.8% | ₹353 Cr 21.7% | ₹451 Cr 10.5% | ₹504 Cr 63.6% | ₹308 Cr 49.5% | ₹206 Cr |
| Depreciation | ₹1.1K Cr 40.8% | ₹795 Cr 1.6% | ₹808 Cr 14.3% | ₹707 Cr 6.8% | ₹662 Cr 0.6% | ₹658 Cr 0.6% | ₹654 Cr 5.8% | ₹618 Cr 51.1% | ₹409 Cr 33.2% | ₹307 Cr |
| PBT | ₹2.9K Cr 7.4% | ₹2.7K Cr 13.6% | ₹2.4K Cr 27.3% | ₹1.8K Cr 50.7% | ₹1.2K Cr 19.7% | ₹1.5K Cr 28.6% | ₹1.2K Cr 111.2% | ₹562 Cr 39.6% | ₹931 Cr 14.4% | ₹1.1K Cr |
| Tax % | 26.0% 7.1% | 28.0% 6.7% | 30.0% 9.1% | 33.0% 10.8% | 37.0% 105.6% | 18.0% 28.6% | 14.0% 36.4% | 22.0% 18.5% | 27.0% 92.9% | 14.0% |
| Net Profit | ₹2.1K Cr 11.9% | ₹1.9K Cr 15.4% | ₹1.7K Cr 33.0% | ₹1.2K Cr 60.2% | ₹777 Cr 37.9% | ₹1.3K Cr 22.1% | ₹1.0K Cr 135.1% | ₹436 Cr 35.7% | ₹678 Cr 27.4% | ₹934 Cr |
| EPS (₹) | 63.92 13.2% | 56.47 15.4% | 48.94 33.0% | 36.79 60.2% | 22.97 37.9% | 36.99 22.2% | 30.28 134.9% | 12.89 35.7% | 20.04 27.4% | 27.59 |
| Div Payout | 59.0% 3.5% | 57.0% 0.0% | 57.0% 5.0% | 60.0% 42.9% | 105.0% 123.4% | 47.0% 11.3% | 53.0% 19.7% | 66.0% 88.6% | 35.0% 40.0% | 25.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 98.8% | ₹85 Cr 0.0% | ₹85 Cr 0.0% | ₹85 Cr 0.0% | ₹85 Cr 0.0% | ₹85 Cr 0.0% | ₹85 Cr |
| Reserves | ₹8.3K Cr 11.6% | ₹7.4K Cr 11.0% | ₹6.7K Cr 10.9% | ₹6.0K Cr 2.7% | ₹5.9K Cr 2.0% | ₹5.8K Cr 21.4% | ₹4.7K Cr 2.1% | ₹4.6K Cr 2.2% | ₹4.5K Cr 6.4% | ₹4.3K Cr |
| Borrowings | ₹2.8K Cr 11.9% | ₹3.2K Cr 20.4% | ₹4.0K Cr 25.1% | ₹5.4K Cr 31.9% | ₹4.1K Cr 16.5% | ₹4.9K Cr 15.7% | ₹5.8K Cr 4.2% | ₹6.0K Cr 6.6% | ₹6.5K Cr 157.5% | ₹2.5K Cr |
| Other Liabilities | ₹4.2K Cr 17.8% | ₹3.6K Cr 0.7% | ₹3.6K Cr 19.2% | ₹3.0K Cr 5.5% | ₹2.9K Cr 14.2% | ₹3.4K Cr 1.1% | ₹3.4K Cr 1.5% | ₹3.4K Cr 6.1% | ₹3.2K Cr 15.3% | ₹2.7K Cr |
| Total Liabilities | ₹15.5K Cr 7.8% | ₹14.4K Cr 0.8% | ₹14.5K Cr 0.7% | ₹14.6K Cr 13.2% | ₹12.9K Cr 8.3% | ₹14.1K Cr 0.5% | ₹14.0K Cr 0.7% | ₹14.1K Cr 0.9% | ₹14.2K Cr 48.3% | ₹9.6K Cr |
Assets | ||||||||||
| Fixed Assets | ₹7.8K Cr 1.3% | ₹7.9K Cr 2.3% | ₹8.1K Cr 0.2% | ₹8.1K Cr 26.4% | ₹6.4K Cr 9.1% | ₹7.1K Cr 6.2% | ₹7.5K Cr 2.8% | ₹7.7K Cr 1.4% | ₹7.9K Cr 113.0% | ₹3.7K Cr |
| CWIP | ₹488 Cr 2.1% | ₹478 Cr 32.4% | ₹361 Cr 52.8% | ₹765 Cr 21.4% | ₹630 Cr 29.1% | ₹889 Cr 24.9% | ₹712 Cr 15.4% | ₹617 Cr 4.6% | ₹647 Cr 24.7% | ₹519 Cr |
| Investments | ₹133 Cr 14.7% | ₹156 Cr 9.8% | ₹173 Cr 13.1% | ₹199 Cr 11.9% | ₹226 Cr 24.9% | ₹181 Cr 8950.0% | ₹2 Cr 99.4% | ₹353 Cr 28.3% | ₹492 Cr 38.8% | ₹804 Cr |
| Other Assets | ₹7.1K Cr 21.3% | ₹5.8K Cr 0.3% | ₹5.8K Cr 5.6% | ₹5.5K Cr 1.8% | ₹5.6K Cr 5.3% | ₹5.9K Cr 3.1% | ₹5.8K Cr 6.8% | ₹5.4K Cr 2.8% | ₹5.2K Cr 14.4% | ₹4.6K Cr |
| Total Assets | ₹15.5K Cr 7.8% | ₹14.4K Cr 0.8% | ₹14.5K Cr 0.7% | ₹14.6K Cr 13.2% | ₹12.9K Cr 8.3% | ₹14.1K Cr 0.5% | ₹14.0K Cr 0.7% | ₹14.1K Cr 0.9% | ₹14.2K Cr 48.3% | ₹9.6K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹2.6K Cr 20.9% | ₹3.3K Cr 37.9% | ₹2.4K Cr 31.3% | ₹1.8K Cr 10.1% | ₹2.0K Cr 43.9% | ₹1.4K Cr 22.5% | ₹1.8K Cr 101.1% | ₹894 Cr 11.4% | ₹1.0K Cr 63.2% | ₹2.7K Cr |
| Investing CF | ₹-549 Cr 243.1% | ₹-160 Cr 93.1% | ₹-2.3K Cr 1091.3% | ₹-196 Cr 55.9% | ₹-444 Cr 293.9% | ₹229 Cr 193.1% | ₹-246 Cr 94.7% | ₹-4.7K Cr 486.1% | ₹-798 Cr 8.2% | ₹-869 Cr |
| Financing CF | ₹-2.3K Cr 17.3% | ₹-2.8K Cr 3710.4% | ₹77 Cr 104.3% | ₹-1.8K Cr 7.9% | ₹-1.7K Cr 6.6% | ₹-1.5K Cr 17.9% | ₹-1.3K Cr 138.5% | ₹3.4K Cr 1870.5% | ₹-193 Cr 86.6% | ₹-1.4K Cr |
| Net Cash Flow | ₹-262 Cr 180.1% | ₹327 Cr 197.3% | ₹110 Cr 163.2% | ₹-174 Cr 95.5% | ₹-89 Cr 221.9% | ₹73 Cr 69.3% | ₹238 Cr 165.0% | ₹-366 Cr 2133.3% | ₹18 Cr 95.9% | ₹437 Cr |
| Free Cash Flow | ₹2.0K Cr 32.9% | ₹3.0K Cr 51.9% | ₹2.0K Cr 21.5% | ₹1.6K Cr 3.8% | ₹1.7K Cr 68.8% | ₹990 Cr 13.0% | ₹1.1K Cr 983.8% | ₹105 Cr 79.9% | ₹523 Cr 75.7% | ₹2.1K Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59d 6.3% | 63d 14.9% | 74d 5.7% | 70d 1.4% | 69d 9.2% | 76d 11.8% | 68d 11.7% | 77d 28.3% | 60d 24.1% | 79d |
| Inventory Days | 334d 7.7% | 310d 4.0% | 298d 19.0% | 368d 19.3% | 456d 26.0% | 362d 13.8% | 318d 25.9% | 429d 34.9% | 318d 1.3% | 314d |
| Days Payable | 239d 15.8% | 284d 26.8% | 224d 10.4% | 250d 28.8% | 351d 1.7% | 345d 0.0% | 345d 22.8% | 447d 25.6% | 356d 31.9% | 523d |
| Cash Conv. Cycle | 154d 73.0% | 89d 39.5% | 147d 21.8% | 188d 8.0% | 174d 87.1% | 93d 121.4% | 42d 28.8% | 59d 181.0% | 21d 116.2% | -130d |
| Working Capital Days | 7d 125.9% | -27d 18.2% | -33d 571.4% | 7d 240.0% | -5d 90.4% | -52d 16.1% | -62d 22.5% | -80d 385.7% | 28d 2900.0% | -1d |
| ROCE | 27.0% 17.4% | 23.0% 15.0% | 20.0% 5.3% | 19.0% 11.8% | 17.0% 13.3% | 15.0% 15.4% | 13.0% 0.0% | 13.0% 31.6% | 19.0% 60.4% | 48.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
HealthcarePharmaceuticals & Biotechnology